MSIF has formed a mutually beneficial relationship with the corporate sector over many years. The development of MS treatments and other products has led to growing interest in the work of the MS International Federation by healthcare companies. As a result they have supported MSIF projects that have benefitted people with MS around the world.

Although much attention has been focused on the pharmaceutical and biotech industries, there are other health sectors that may wish to support MSIF and its member MS societies. These include manufacturers and suppliers of medical devices and aids to daily living, dietary supplements, health management organisations, nursing/ homecare agencies and insurers.

Healthcare companies are important stakeholders in the MS space and where we have shared goals we welcome their support of our work. We also recognise that not all of our goals are aligned so do not accept any interference or influence over any programme design or delivery. In support of this we also always try to secure multi-stakeholder funding for projects to reduce the risk of individual influence.

To acknowledge the unique role of healthcare companies in the MS space we have two policies covering our engagement with them. One covers relationships involving financial arrangements, and the other covers non-financial relationships.

2017 healthcare industry support

The information below shows the exact amount we received from the healthcare industry in 2017 and the programmes they supported.


Sanofi Genzyme – Total: £165,741

  • Access to effective treatment £9,575
  • Informed decision making (Communicating about MS): £70,674
  • World MS Day: £18,998
  • Atlas of MS: £9,499
  • Arabic speaking region capacity building: £37,997
  • Latin America capacity building: £18,998

Merck – Total: £125,000

  • Access to effective treatment £10,000
  • Informed decision making (Communicating about MS): £40,000
  • World MS Day: £20,000
  • Atlas of MS: £10,000
  • Arabic speaking region capacity building: £10,000
  • Latin America capacity building: £10,000
  • Global capacity building: £10,000
  • Kiss Goodbye to MS £15,000

Biogen – Total: £115,000

  • Access to effective treatment £10,000
  • Informed decision making (Communicating about MS): £20,000
  • World MS Day: £20,000
  • Atlas of MS: £10,000
  • Arabic speaking region capacity building: £20,000
  • Latin America capacity building: £10,000
  • Global capacity building: £10,000
  • Kiss Goodbye to MS £15,000

Roche – Total: £130,000

  • Access to effective treatment £10,000
  • Informed decision making (Communicating about MS): £35,000
  • World MS Day: £15,000
  • Atlas of MS: £10,000
  • Arabic speaking region capacity building: £10,000
  • Latin America capacity building: £10,000
  • Global capacity building: £40,000

Teva – Total: £110,000

  • Access to effective treatment £10,000
  • Informed decision making (Communicating about MS): £20,000
  • World MS Day: £20,000
  • Atlas of MS: £10,000
  • Global capacity building: £50,000

Med Day Pharmaceutical – Total: £50,000

  • Access to effective treatment £10,000
  • Informed decision making (Communicating about MS): £10,000
  • World MS Day: £10,000
  • Atlas of MS: £10,000
  • Global capacity building: £10,000

Celgene – Total: £7,800

  • World MS Day: £7,800 ($10,000 – exact amount TBC)

Will Pharma – Total: £1,319

  • Unsolicited £1,319

Page Tags: